
    
      This is a prospective open label, randomized, multi-center registry. One hundred patients who
      received fondaparinux within the 24 hours prior to presentation to the coronary
      catheterization lab and who are suitable for percutaneous coronary intervention. The patients
      will be randomized in a 1:1 fashion to either unfractionated heparin or bivalirudin during
      the angioplasty. All patients will be followed throughout the duration of the hospital stay.
    
  